Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease?

Curr Neurovasc Res. 2004 Apr;1(2):183-90. doi: 10.2174/1567202043480143.

Abstract

Multiple sclerosis is an inflammatory disease of the CNS and a leading cause of disability. Inflammatory mediators play an orchestrating part in lesional development leading to symptoms. Chemokines -- chemoattractant cytokines -- regulate the inflammatory composite of the MS lesion. This review focuses on the present data regarding CXCL10 (previously known as IP-10) and CXRC3 in multiple sclerosis, since consistent data has suggested that this chemokine/chemokine receptor pair has a pivotal role in leukocyte recruitment into the central nervous system (CNS) in multiple sclerosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Central Nervous System / metabolism*
  • Chemokine CXCL10
  • Chemokines, CXC / metabolism*
  • Humans
  • Ligands
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / metabolism*
  • Receptors, CXCR3
  • Receptors, Chemokine / metabolism*

Substances

  • CXCR3 protein, human
  • Chemokine CXCL10
  • Chemokines, CXC
  • Ligands
  • Receptors, CXCR3
  • Receptors, Chemokine